Latest Stock Market News

Several Indian companies are delaying their initial public offerings. This is due to weak investor sentiment and global economic uncertainty. Avanse Financial and Anthem Biosciences are among those postponing plans. Geopolitical tensions and global trade frictions are contributing factors. The market debut of Ather Energy will be a test of investor appetite.

The rupee weakened against the US dollar. This happened due to a stronger dollar index and weaker Asian currencies. Geopolitical tensions between India and Pakistan also affected investor sentiment. Crude oil prices and foreign fund inflows offered some support. Markets are reacting to potential policy changes. The rupee s movement is expected to be volatile. Sensex and Nifty also experienced declines.

Indian pharmaceutical stocks experienced a significant decline. This followed US President Donald Trump s executive order. The order aims to boost domestic drug production in the United States. Concerns arose about potential disruptions for Indian drug exporters. These exporters heavily rely on the US market. The Nifty Pharma index saw a drop. Companies like Lupin, Aurobindo Pharma, and Cipla faced losses.

Gold prices surged on Tuesday due to concerns over President Trump s proposed tariffs, increasing safe-haven demand. Investors are keenly awaiting the Federal Reserve s policy meeting for insights into future rate adjustments, especially with the current rate held steady since last December. Spot gold rose significantly, alongside silver and other metals, reflecting market uncertainty.

When the RSI value crosses above 50 from below, it signals that the Relative Strength Index (RSI) is rising, indicating strengthening momentum in the stock s price. This suggests a potential upward trend.

Explore the promising landscape of India s defense sector, driven by strategic government initiatives and robust growth potential. Discover key players and their performance metrics as the sector gears up for a transformative era.

The Nifty Pharma index was trading 0.88 per cent down at 21585.05.

CCL Products shares soared nearly 16% following a robust January-March quarter. The company s net profit jumped 56.35% to Rs 101.9 crore. Revenue grew 15% to Rs 836 crore, driven by exports and Vietnam facility output. EBITDA rose 38.3% to Rs 163.3 crore. Analysts predict an 11% upside, with a Buy recommendation. The stock surged 23% in one month.

April saw EPS downgrades for 70% of Nifty50 firms, led by Zomato with a 15.1% cut. IT, consumer, and auto sectors faced sharp estimate reductions. Despite strong Q4 beat-miss ratios, FY26 forecasts declined due to global headwinds and underperformance in IT, FMCG, and financials.

Following the Pahalgam attack, Pakistan s KSE-100 index fell nearly 4%. Fears of military escalation rattled investors. India s Sensex rose 1.5%, defying regional risks. Moody s warned of economic strain on Pakistan. India suspended the Indus Waters Treaty. Foreign investors remained confident in India. Tensions between the two countries remain high. The historical context shows Indian markets have weathered such tensions.